Current antiviral therapy for chronic hepatitis B

Journal of Korean Medical Science

Volumn 19, Issue 4, 2004, Pages 489-494

  Lim, Young Suk ^a   Dong, Jin Suh ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adefovir Dipivoxil; Antiviral Agents; Hepatitis B; Hepatitis B Virus; Interferon alpha; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON;

CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MYALGIA; NEPHROTOXICITY; NONHUMAN; REMISSION; REVIEW; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 4444293477     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.4.489     Document Type: Review

References (43)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
3. EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol 2003; 38: 533-40.
4. Core working party for Asia-Pacific consensus on hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15: 825-41.
5. Liaw YF, Leung N, Guan R, Lau GK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 2003; 18: 239-45.
6. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
7. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-6.
8. Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Lee MS, Park CK, Yoo JY. Seroepidemiology of HBV infection in South Korea, 1995 through 1999. Korean J Intern Med 2001; 16: 153-9.
9. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002; 17: 457-62.
10. Chang MH. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 2000; 15 (Suppl): E16-9.
11. Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, Calzia R, Realdi G. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99: 805-10.
12. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
13. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001; 8: 311-21.
14. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003; 23: 81-8.
15. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
16. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, Bodicky C, Miller B, Denham C. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
17. Guan R. Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 2000; 15 (Suppl): E34-40.
18. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-9.
19. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-63.
20. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
21. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
22. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
23. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
24. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
25. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN; On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 yr of therapy. Hepatology 2001; 33: 1527-32.
26. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
27. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
28. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
29. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999; 29: 939-45.
30. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 257-62.
31. Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19: 323-9.
32. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.
33. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
34. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208-12.
35. Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, Park NH, Lee HC, Lee YS, Suh DJ. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614-9.
36. Lee HC, Suh DJ, Ryu SH, Kim H, Shin JW, Lim YS, Chung YH, Lee YS. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003; 52: 1779-83.
37. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiftman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxilfor the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxilfor the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
39. Peters MG, Hann H-W, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray DF, Sullivan M, Kleber K ER, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
40. Perrillo R, Hann H-W, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
41. Choi WB, Suh DJ, Kim SH, Lim YS, Lee HC, Chung YH, Lee YS. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistant decompensated liver disease. (abstract). Korean J Hepatol 2004; 10: S103.
42. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
43. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-40.